PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.07 - 0.07
0.04 - 0.15
840.0K / 2.59M (Avg.)
-2.33 | -0.03
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.65%
Revenue growth below 50% of Industrials median of 5.81%. Jim Chanos would be concerned about potential secular decline.
19.79%
Gross profit growth exceeding 1.5x Industrials median of 2.59%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
25.53%
EBIT growth of 25.53% while Industrials median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
81.17%
Operating income growth of 81.17% while Industrials median is zero. Walter Schloss might see a modest advantage that can expand.
13.97%
Net income growth of 13.97% while Industrials median is zero. Walter Schloss might see potential if moderate gains can keep rising.
13.91%
EPS growth of 13.91% while Industrials median is zero. Walter Schloss might see a slight edge that could compound over time.
13.91%
Diluted EPS growth of 13.91% while Industrials median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
142.69%
10Y revenue/share CAGR exceeding 1.5x Industrials median of 18.67%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
142.69%
5Y revenue/share growth exceeding 1.5x Industrials median of 7.67%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-2.83%
Negative 3Y CAGR while Industrials median is 0.58%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.60%
Net income/share CAGR exceeding 1.5x Industrials median of 8.79% over a decade. Joel Greenblatt might see a standout compounder of earnings.
80.60%
5Y net income/share CAGR > 1.5x Industrials median of 8.97%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
3283.33%
3Y net income/share CAGR of 3283.33% while Industrials median is zero. Walter Schloss might see a small advantage that can be scaled further.
81.84%
Equity/share CAGR exceeding 1.5x Industrials median of 28.75% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
81.84%
5Y equity/share CAGR > 1.5x Industrials median of 19.06%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
-36.25%
Negative 3Y equity/share growth while Industrials median is 9.90%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.51%
SG&A decline while Industrials grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.